|
EP3641742A2
|
|
Hydroxynorketamine for the use in the treatment of depression
|
|
EP3372225A1
|
|
Novel dosage form
|
|
EP3290027A1
|
|
Method and composition for the treatment of opioid induced constipation
|
|
US2017087150A1
|
|
Method and composition for the treatment of opioid induced constipation
|
|
WO2016193456A2
|
|
Opioid receptor antagonist for use in treating patients with severe constipation
|
|
EP3302476A2
|
|
Opioid receptor antagonist for use in treating patients with severe constipation
|
|
DE102016102887A1
|
|
Oral dosage form of a dabigatran prodrug for the treatment of diseases
|
|
EP3229785A2
|
|
Naloxone monopreparation and multi-layer tablet
|
|
US2016256453A1
|
|
Opioid receptor antagonist for use in treating patients with severe constipation induced by high opiate dosage regimen
|
|
US2016256452A1
|
|
Composition Of Opioid Receptor Antagonists For Use In Treatment Of Constipation With Highly Increased Whole Gut Transit Time
|
|
US2016256451A1
|
|
Dosage of naloxone
|
|
EP3131533A1
|
|
Oral dosage form of ketamine
|
|
US2015238420A1
|
|
Naloxone mono preparation and multilayer tablet
|
|
HUE031251T2
|
|
Controlled release oral dosage form comprising oxycodone
|
|
WO2008155620A1
|
|
Dosage form containing dispersible matrix of sustained release granules
|
